Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;1999(2):CD001362.
doi: 10.1002/14651858.CD001362.

Regimens of less than six months for treating tuberculosis

H Gelband  1
Affiliations

Regimens of less than six months for treating tuberculosis

H Gelband. Cochrane Database Syst Rev. 2000.

Abstract

Background: WHO recommends 6 months of treatment in TB programmes.

Objectives: The purpose of this review is to assess the effects of regimens lasting less than 6 months compared with longer regimens in the treatment of active TB.

Search strategy: Search strategy: MEDLINE 1955-, Cochrane Infectious Diseases Trials Register, existing reviews, and researchers in the field. Date of the most recent search: January 1999.

Selection criteria: Randomized trials comparing two or more TB drug regimens, in which at least one regimen was <6 months and it was compared with at least one regimen that lasted longer, in any patients with active TB.

Data collection and analysis: One reviewer extracted data and assessed trial quality.

Main results: Seven trials with a total of 9 comparisons of <6 months (range: 2-5 months) versus longer treatment were included. About 2200 patients were in the shorter regimens and about 1900 in the longer regimens (the same comparison groups were used for more than one shorter regimen, in two studies). Relapse rates were consistently higher after shorter duration treatment regimens, regardless of the comparison made, though they were all relatively low. Results were significantly better in the longer groups in the meta-analyses of 2, 3, and 4 months of treatment vs longer treatment (Peto OR = 6.1 [95%CI 2.19,17.01], 3.67 [2.42,5.58], 3.64 [1.71,7. 75] but not in the single trial of 5 vs. 7 months (Peto OR = 2.24 [0. 90,5.59]. Relapse rates after longer (comparison) regimens ranged from 0-7% at one year (or more), and in the shorter treatment arms, they ranged from 1-9% in 8 trials, and18% relapsed in the one remaining. There was little or no difference in the rates of adverse reactions or toxicity requiring a change of regimen or discontinuation of treatment. The "sterilizing efficacy" at the end of treatment varied little among treatments, providing no predictive value for relapse rates. Few or no deaths were reported in the individual trials, and in no case did enough deaths occur for a comparison of short vs. long regimens.

Reviewer's conclusions: Longer periods of treatment (at least up to 6 months) result in higher success rates in patients with active TB, but the differences are small. Under field conditions, where adherence to treatment is a big problem, and shorter regimens might improve adherence, these differences may not be evident. A comparison of <6 months vs. 6 months of treatment under programme conditions would be needed to determine this.

PubMed Disclaimer

Conflict of interest statement

I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of the review (e.g. employment, consultancy, stock ownership, honoraria, expert testimony).

Figures

1.1
1.1. Analysis
Comparison 1 2 months vs longer, Outcome 1 Relapse within 12 months of finishing treatment.
1.2
1.2. Analysis
Comparison 1 2 months vs longer, Outcome 2 Toxicity requiring interruption, alteration, or cessation.
2.1
2.1. Analysis
Comparison 2 3 months vs longer, Outcome 1 Relapse within 12 months of finishing treatment.
2.2
2.2. Analysis
Comparison 2 3 months vs longer, Outcome 2 Toxicity requiring interruption, alteration, or cessation.
3.1
3.1. Analysis
Comparison 3 4 months vs longer, Outcome 1 Relapse within 12 months of finishing treatment.
3.2
3.2. Analysis
Comparison 3 4 months vs longer, Outcome 2 Toxicity requiring interruption, alteration, or cessation.
4.1
4.1. Analysis
Comparison 4 5 months vs longer, Outcome 1 Relapse within 12 months of finishing treatment.
See this image and copyright information in PMC

References

References to studies included in this review

Agra 1981 {published data only}
    1. Mehrotra ML, Gautam KD, Chaube CK. Shortest possible acceptable, effective ambulatory chemotherapy in pulmonary tuberculosis. Am Rev Respir Dis 1981;124:239‐244. - PubMed
Germany 1986 {published data only}
    1. Eule H, Beck H, Evers H, et al. Daily ultrashort chemotherapy and intermittent short‐term chemotherapy with 4 drugs of communicable pulmonary tuberculosis treated for the first time. Results of a cooperative multicenter study [Tagliche ultrakurze Chemotherapie und intermittierende Kurzzeit‐Chemotherapie mit 4 Medikamenten bei erstbehandelten ansteckenden Lungentuberkulosen]. Z Erkrank Atm org 1986;167:29‐41. - PubMed
Hong Kong 1979a {published data only}
    1. Hong Kong Chest Service, Tuberculosis Research Centre, Madras, India, and British Medical Research Council. Sputum‐smear‐negative pulmonary tuberculosis: Controlled trial of 3‐month and 2‐month regimens of chemotherapy. Lancet 1979;i:1361‐1363. - PubMed
Hong Kong 1989a {published data only}
    1. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled trial of 3‐month, 4‐month, and 6‐month regimens of chemotherapy for sputum‐smear‐negative pulmonary tuberculosis. Am Rev Respir Dis 1989;139:871‐876. - PubMed
S. India 1983 {published data only}
    1. Santha T, Nazareth O, Krishnamurthy S, et al. Treatment of pulmonary tuberculosis with short course chemotherapy in South India‐‐5‐year follow up. Tubercle 1989;70:229‐234. - PubMed
    1. Tuberculosis Research Centre. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum‐positive patients with pulmonary tuberulosis in South India. Tubercle 1983;64:73‐91. - PubMed
S. India 1986 {published data only}
    1. Balasubramanian R, Sivasubramanian S, Vijayan VK, et al. Five year results of a 3‐month and two 5‐month regimens for the treatment of sputum‐positive pulmonary tuberculosis in South India. Tubercle 1990;71:253‐258. - PubMed
    1. Tuberculosis Research Centre, Madras and National Tuberculosis Institute, Bangalore. A controlled clinical trial of 3‐ and 5‐month regimens in the treatment of sputum‐positive pulmonary tuberculosis in South India. Am Rev Respir Dis 1986;134:27‐33. - PubMed
Singapore 1979a {published data only}
    1. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six‐month and four‐month regimens of chemotherapy in the treatment of pulmonary tuberculosis. American Review of Respiratory Diseases 1979;119:579‐585. - PubMed
    1. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six‐month and four‐month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 1981;62:95‐102. - PubMed
    1. Singapore Tuberculosis Service/British Medical Research Council. Long‐term follow‐up of a clinical trial of six‐month and four‐month regimens of chemotherapy in the treatment of pulmonary tuberculosis. American Review of Respiratory Diseases 1986;133:779‐783. - PubMed

References to studies excluded from this review

East Africa 1978 {published data only}
    1. East African and British Medical Research Councils. Controlled clinical trial of five short‐course (4‐month) chemotherapy regimens in pulmonary tuberculosis. Lancet 1978;ii:334‐338. - PubMed
France 1976 {published data only}
    1. Kreis B, Pretet, Birenbaum J, et al. Two three‐month treatment regimens for pulmonary tuberculosis. Bull Int Union Tuberc 1976;51:71‐75. - PubMed

References to studies awaiting assessment

Bock 2001 {published data only}
    1. Bock NN, Rogers T, Tapia JR, Herron GD, DeVoe B, Geiter LJ. Acceptability of short‐course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest 2001;119(3):833‐7. - PubMed
Borisova 2003 {published data only}
    1. Borisova MI, Stakhanov VA, Sharkova TI, Ivashchenko NA. The use of fenazid in patients with pulmonary tuberculosis with poor isoniazid tolerance [Primenenie fenazida u bol'nykh tuberkulezom legkikh s plokhoi perenosimost'iu izoniazida]. Problemy Tuberkuleza 2003;7:34‐7. - PubMed
Gravendeel 2003 {published data only}
    1. Gravendeel JM, Asapa AS, Becx‐Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side‐effects, complaints and treatment results of a single‐drug short‐course regimen with a four‐drug fixed‐dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis 2003;83(1‐3):183‐6. - PubMed
Hernandez 1993 {published data only}
    1. Hernández Forero JC. A controlled clinical trial of 4 months regimens in the shortened treatment of tuberculous pleural efusion. Apresentada a Universidad El Bosque. Facultad de Medicina para obtençao do grau de Postgrado Medicina Interna [Estudio clínico controlado de un esquema de 4 meses en el tratamiento acortado de la tuberculosis pleura]. Bogotá, D.C, 1993.
Jasmer 2002 {published data only}
    1. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff, E, et al. Short‐course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Annals of Internal Medicine 2002;137(8):640‐7. - PubMed
Lwilla 2003 {published data only}
    1. Lwilla F, Schellenberg D, Masanja H, Acosta C, Galindo C, Aponte J, et al. Evaluation of efficacy of community‐based vs. institutional‐based direct observed short‐course treatment for the control of tuberculosis in Kilombero district, Tanzania. Tropical Medicine and International Health 2003;8(3):204‐10. - PubMed
Matteelli 1999 {published data only}
    1. Matteelli A, Olliaro P, Signorini L, Cadeo G, Scalzini A, Bonazzi L, et al. Tolerability of twice‐weekly rifabutin‐isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV‐infected subjects: a pilot study. International Journal of Tuberculosis and Lung Disease 1999;3(11):1043‐6. - PubMed
Mawer 2001 {published data only}
    1. Mawer C, Ignatenko N, Wares D, Strelis A, Golubchikova V, Yanova G, et al. Comparison of the effectiveness of WHO short‐course chemotherapy and standard Russian antituberculous regimens in Tomsk, western Siberia. Lancet 2001;358(9280):445‐9. - PubMed
Sanchez 2004 {published data only}
    1. Sanchez‐Arcilla I, Vilchez JM, Garcia de la Torre M, Fernandez X, Noguerado A. Treatment of latent tuberculosis among homeless population. Comparison between wo therapeutic approaches [Infeccion tuberculosa latente en poblacion indigente. Comparacion de dos pautas terapeuticas]. Medicina Clinica (Barc) 2004;122(2):57‐9. - PubMed
Teo 2002 {published data only}
    1. Teo SK, Tan KK, Khoo TK. Four‐month chemotherapy in the treatment of smear‐negative pulmonary tuberculosis: results at 30 to 60 months. Annals of the Academy of Medicine, Singapore 2002;31(2):175‐81. - PubMed
Yu 2001 {published data only}
    1. Yu D, Wang J, Hu X. Clinical research of pasinizid on retreated sputum positive pulmonary tuberculosis in senilities. Zhonghua Jie He He Hu Xi Za Zhi 2001;24(10):608‐10. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources